APC 366
Alternative Names: APC 366-A; APC 366-C; APC 366-RLatest Information Update: 15 Oct 1998
At a glance
- Originator Celera Genomics Group
- Class Antiasthmatics; Antithrombotics; Nonsteroidal anti-inflammatories
- Mechanism of Action Mast cell tryptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 15 Oct 1998 Discontinued-II for Asthma in United Kingdom (Inhalation)
- 15 Oct 1998 Discontinued-II for Asthma in USA (Inhalation)
- 17 Sep 1998 Axys Pharmaceuticals has filed an IND for a dry powder inhaler formulation of APC 366